Spoken Alpha
ARCT
Arcturus Therapeutics Holdings Inc.
Overview
Arcturus Therapeutics designs and develops messenger RNA medicines and vaccines for rare genetic diseases and infectious diseases.
Arcturus Therapeutics Holdings Inc is a Healthcare company operating in Biotechnology with a $201.2M market cap.
Most recent earnings call: Q1 FY26 on May 8, 2026.
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-05-0819 Q&A exchanges
- Q4 FY2025Earnings2026-03-0322 Q&A exchanges
- Q3 FY2025Earnings2025-11-1028 Q&A exchanges
- Q2 FY2025Earnings2025-08-1125 Q&A exchanges
- Q1 FY2025Earnings2025-05-1231 Q&A exchanges
- Q4 FY2024Earnings2025-03-0625 Q&A exchanges
- Q3 FY2024Earnings2024-11-0732 Q&A exchanges
- Q2 FY2024Earnings2024-08-0525 Q&A exchanges
- Q1 FY2024Earnings2024-05-0818 Q&A exchanges
- Q4 FY2023Earnings2024-03-0726 Q&A exchanges
- Q3 FY2023Earnings2023-11-1431 Q&A exchanges
- Q2 FY2023Earnings2023-08-0729 Q&A exchanges
- Q1 FY2023Earnings2023-05-0929 Q&A exchanges
- Q4 FY2022Earnings2023-03-2817 Q&A exchanges
- Q3 FY2022Earnings2022-11-0927 Q&A exchanges
- Q2 FY2022Earnings2022-08-0935 Q&A exchanges
- Q1 FY2022Earnings2022-05-0916 Q&A exchanges
- Q4 FY2021Earnings2022-02-2831 Q&A exchanges
- Q3 FY2021Earnings2021-11-0830 Q&A exchanges
- Q2 FY2021Earnings2021-08-1033 Q&A exchanges
- Q1 FY2021Earnings2021-05-1027 Q&A exchanges
History
Earnings history
Reported quarters with consensus, surprise, and 1-day reaction context.
Track Record
SampleSpoken Alpha tracks ARCT's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters but stock falls 60% of the time
SampleWhen a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $4.41 | $3.49 | +26.5% | +1.2% | +1.5% |
| Q4 FY2026 | $4.79 | $3.60 | +33.1% | -0.2% | +0.7% |
| Q3 FY2026 | $4.48 | $3.38 | +32.5% | -7.7% | -9.2% |
| Q2 FY2026 | $4.81 | $3.63 | +32.5% | +1.3% | +2.8% |
| Q1 FY2025 | $4.57 | $3.49 | +31.0% | -0.8% | -2.3% |
| Q4 FY2025 | $4.66 | $3.59 | +29.7% | +1.6% | +3.0% |
| Q3 FY2025 | $4.63 | $3.58 | +29.3% | -7.9% | -6.0% |
| Q2 FY2025 | $4.35 | $3.61 | +20.4% | +1.6% | +0.4% |
| Q1 FY2024 | $4.54 | $3.46 | +31.1% | -5.9% | -7.5% |
| Q4 FY2024 | $4.31 | $3.58 | +20.3% | -0.6% | -3.4% |
Guidance change history
Sample- Q1 FY2026Raised2026-04-15
- Q4 FY2026Raised2026-13-15
- Q3 FY2026Raised2026-10-15
- Q2 FY2026Raised2026-07-15
- Q1 FY2025Raised2025-04-15
- Q4 FY2025Raised2025-13-15
- Q3 FY2025Raised2025-10-15
- Q2 FY2025Raised2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Joseph E PayneCEO2 yr 6 mo21 callsCurrentSample
CEO since 2023 • 8/12 beats (67%) • guidance suspended Q1 FY2026
- Andy SassineCFO2 yr 6 mo19 callsCurrentSample
CFO since 2023 • 5/12 beats (42%) • last guidance raise Q2 FY2026
- Pad ChivukulaCOO2 yr 9 mo8 callsCurrentSample
COO since 2023 • 7/12 beats (58%) • last call held guidance Q2 FY2026
- Lance KurataChief Legal Officer2 yr 6 mono recorded callsCurrentSample
OTHER_C_SUITE since 2023 • 7/12 beats (58%) • guidance suspended Q2 FY2026
- Joseph RobertsController6 mono recorded callsCurrentSample
OTHER since 2025 • 2/4 beats (50%) • last guidance cut Q2 FY2026
- Keith C KummerfeldSee Remarks0 mono recorded callsFormerSample
OTHER since 2023 • 5/12 beats (42%) • last call held guidance Q3 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for ARCT.
$ curl https://api.spokenalpha.com/v1/companies/ARCTFAQ
Frequently asked about ARCT
Where can I find Arcturus Therapeutics Holdings Inc.'s (ARCT) earnings call transcripts?
Spoken Alpha indexes ARCT's earnings call transcripts at https://spokenalpha.com/companies/ARCT. Each call links to attributed speakers and parsed analyst Q&A. Arcturus Therapeutics Holdings Inc.'s own investor relations page is at https://ir.arcturusrx.com/press-releases.
When was Arcturus Therapeutics Holdings Inc.'s most recent earnings call?
Arcturus Therapeutics Holdings Inc. (ARCT) held its most recent earnings call on 2026-05-08, covering fiscal Q1 2026.
What sector is ARCT in?
Arcturus Therapeutics Holdings Inc. (ARCT) operates in the Healthcare sector (Biotechnology industry).